A phase I/II study of Bevacizumab combined with Cisplatin and Pemetrexed for Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer

INTERVENTION: Cislpatin (75mg/m2 day1) + Pemetrexed(500mg/m2 day1) + Bevacizumb (15mg/kg day1) q3weeks 4(‐6)cycles followed by Bevacizumab (15mg/kg day1)q3weeks until disease progression CONDITION: non‐squamous non‐small‐cell lung cancer PRIMARY OUTCOME: STEP1; Safety; STEP2 ; Overall Response Rate SECONDARY OUTCOME: Progression‐free survival (PFS) ; Overall Survival; Overall Response Rate for combination CT ; Adverse events INCLUSION CRITERIA: 1) Histologically or cytologically confirmed non‐sqamous non‐small‐cell lung cancer 2) Stage III/IV without indication for curative resection and post‐operative recurrent disease 3) Patients aged 20‐74 years 4) ECOG performance status 0‐1 5) Target lesion is measurable(RECISTver1.1) 6) Chemotherapy naive 7) Excepted to live over 3 months after administration day 8) More than 2 months rest period after radiation 9) Adequate organ function 10) Written informed consent from the patients